Abstract
An enhanced understanding of the immunopathology of rheumatoid arthritis (RA) has led to the development of novel therapies that target specific events occurring in the immune cascade that underlies the disease. In December 2005, abatacept became the first therapy to be approved by the US Food and Drug Administration for the treatment of adult patients with moderately to severely active RA who have exhibited an inadequate response to traditional disease-modifying antirheumatic drugs or tumor necrosis factor antagonists. This article summarizes the characteristics and clinical profile of abatacept. Abatacept is a fully human soluble recombinant fusion protein that acts by binding to CD80/CD86 on antigen-presenting cells and inhibiting interaction with CD28 on T cells, thus preventing one of the co-stimulatory signals needed for full T-cell activation. It is indicated for reducing signs and symptoms of the disorder, inducing a major clinical response, slowing the progression of structural damage, and improving physical function in this patient population. Data on abatacept compiled to date demonstrate significant efficacy, combined with a consistent safety profile and tolerability, in a wide range of patients with RA, including those with an inadequate response to methotrexate or to tumor necrosis factor antagonists.
Similar content being viewed by others
References
Lee DM, Weinblatt ME. Rheumatoid arthritis.Lancet. 2001; 358: 903–911.
Genentech. Rituxan® (rituximab) prescribing information. Available at: www.rituxan.com. Accessed August 3, 2006.
Bristol-Myers Squibb. Orencia® (abatacept) prescribing information. Available at: www.orencia.com. Accessed August 3, 2006.
Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis.N Engl J Med. 2001; 344: 907–916.
Yamada A, Salama AD, Sayegh MH. The role of novel T cell costimulatory pathways in autoimmunity and transplantation.J Am Soc Nephrol. 2002; 13: 559–575.
Kremer JM. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis.J Clin Rheumatol. 2005; 11(3 suppl): S55-S62.
Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion.Arthritis Rheum. 2002; 46: 1470–1479.
Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.N Engl J Med. 2003; 349: 1907–1915.
Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial.Arthritis Rheum. 2005; 52: 2263–2271.
Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial.Ann Rheum Dis. 2007; 66: 228–234.
Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.Ann Intern Med. 2006; 144: 865–876.
Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.N Engl J Med. 2005; 353: 1114–1123.
Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a 1 year randomized, placebo-controlled study.Arthritis Rheum. 2006; 54: 2807–2816.
Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate.Arthritis Rheum. 2004; 50: 1412–1419.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lundquist, L. Abatacept: A novel therapy approved for the treatment of patients with rheumatoid arthritis. Adv Therapy 24, 333–345 (2007). https://doi.org/10.1007/BF02849902
Issue Date:
DOI: https://doi.org/10.1007/BF02849902